We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEMI
176
DELISTED
Chembio diagnostics, Inc.
CEMI
$1.04M 0.05%
+219,109
New +$1.13M
PBYI icon
177
CALL
Puma Biotechnology
PBYI
$404M
$1.03M 0.05%
+100,000
New +$1.01M
CYRX icon
178
CryoPort
CYRX
$761M
$1M 0.04%
+22,900
New +$1.09M
ALEC icon
179
Alector
ALEC
$168M
$870K 0.04%
57,500
+57,179
+17,813% +$711K
ALT icon
180
Altimmune
ALT
$552M
$851K 0.04%
75,445
-38,323
-34% -$452K
ETNB
181
DELISTED
89bio
ETNB
$799K 0.04%
32,799
-307,437
-90% -$7.86M
MRTX
182
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$781K 0.03%
3,557
-35,000
-91% -$7.57M
QNCX icon
183
CALL
Quince Therapeutics
QNCX
$22.9M
$776K 0.03%
140
+125
+833% +$1.11M
IFRX icon
184
InflaRx
IFRX
$250M
$754K 0.03%
149,750
– –
APLT
185
DELISTED
Applied Therapeutics
APLT
$726K 0.03%
+33,002
New +$687K
ALBO
186
DELISTED
Albireo Pharma Inc
ALBO
$633K 0.03%
+16,883
New +$614K
KALA icon
187
KALA BIO
KALA
$14.1M
$594K 0.03%
35
-146
-81% -$2.75M
PBYI icon
188
Puma Biotechnology
PBYI
$404M
$563K 0.02%
54,901
– –
AVTX icon
189
Avalo Therapeutics
AVTX
$965M
$536K 0.02%
70
– –
RCUS icon
190
PUT
Arcus Biosciences
RCUS
$3.55B
$532K 0.02%
+20,500
New +$496K
ADVM
191
PUT
DELISTED
Adverum Biotechnologies
ADVM
$486K 0.02%
4,480
-25,000
-85% -$3.09M
COGT icon
192
Cogent Biosciences
COGT
$6.65B
$469K 0.02%
+41,762
New +$459K
WHWK
193
Whitehawk Therapeutics
WHWK
$190M
$468K 0.02%
31,719
-231,112
-88% -$4.94M
BMY.RT
194
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$444K 0.02%
644,021
-1,155,979
-64% -$2.46M
ASMB icon
195
Assembly Biosciences
ASMB
$498M
$439K 0.02%
6,039
-7,083
-54% -$831K
MREO
196
Mereo BioPharma
MREO
$54.7M
$416K 0.02%
1,146,308
-50,000
-4% -$125K
ABUS icon
197
Arbutus Biopharma
ABUS
$857M
$408K 0.02%
115,000
– –
ASLN
198
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$405K 0.02%
+50,161
New +$3.68M
VIRX
199
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$398K 0.02%
+57,143
New +$298K
AVDL
200
DELISTED
Avadel Pharmaceuticals
AVDL
$366K 0.02%
54,694
– –
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.